Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Assets: 2017-2025

Historic Assets for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $518.6 million.

  • Cidara Therapeutics' Assets rose 219.50% to $518.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $518.6 million, marking a year-over-year increase of 219.50%. This contributed to the annual value of $214.8 million for FY2024, which is 220.45% up from last year.
  • Latest data reveals that Cidara Therapeutics reported Assets of $518.6 million as of Q3 2025, which was down 2.93% from $534.3 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Assets registered a high of $534.3 million during Q2 2025, and its lowest value of $39.4 million during Q2 2022.
  • Its 3-year average for Assets is $193.6 million, with a median of $162.3 million in 2024.
  • Its Assets has fluctuated over the past 5 years, first tumbled by 38.25% in 2022, then skyrocketed by 263.70% in 2025.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Assets stood at $75.3 million in 2021, then crashed by 36.96% to $47.5 million in 2022, then skyrocketed by 41.15% to $67.0 million in 2023, then spiked by 220.45% to $214.8 million in 2024, then spiked by 219.50% to $518.6 million in 2025.
  • Its Assets was $518.6 million in Q3 2025, compared to $534.3 million in Q2 2025 and $191.7 million in Q1 2025.